{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:17:55Z","timestamp":1788268675494,"version":"build-2803163510"},"reference-count":18,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glycogen storage disease type Ia (GSDIa) is a rare, inherited, autosomal recessive deficiency of glucose-6-phosphatase (G6Pase), an enzyme necessary in glycogenolysis and gluconeogenesis. To maintain normal blood glucose levels and ensure survival, individuals living with GSDIa must frequently consume complex carbohydrates (eg, uncooked cornstarch). Dietary management can result in chronic complications and significant patient burden. DTX401 (pariglasgene brecaparvovec) is an investigational adeno-associated virus serotype 8 vector (AAV8)\u2013based gene therapy designed to restore endogenous glucose production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objectives\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patient experience interviews were conducted as part of an open-label, phase 1\/2 dose-escalation trial (NCT03517085) evaluating the safety and efficacy of DTX401 in adults \u226518 years with GSDIa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Telephone interviews were conducted at Weeks 24, 52, and 104, using a semistructured interview guide. Qualitative interview data were audio recorded, transcribed, coded, and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most (86%; n\u2009=\u20096\/7) reported overall symptom improvement and reduced burden following DTX401 treatment. Three (43%) reported no negative outcomes following gene therapy; 4 (57%) mentioned at least one negative change attributed to instances of blood sugar instability, lifestyle, or diet adjustments. Satisfaction fluctuated across timepoints; however, most were somewhat satisfied\/very satisfied with gene therapy at Weeks 24 (80%), 52 (86%), and 104 (86%). No participants reported being very dissatisfied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"discussion\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Following DTX401 treatment, most participants reported substantial reduction in cornstarch intake and corresponding improvements in symptoms, physical function, diet management, emotional function, self-perception, social function, sleep quality, work performance, and overall health. Few negative changes were reported. While some results regarding met expectations were mixed, most indicated they would still want gene therapy even if they had to continue cornstarch and if they had continued diet restrictions, and most reported satisfaction with treatment. While the study had limitations, interview results suggest that DTX401 helps to address aspects of the condition and treatment that patients have identified as burdensome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most interviewees in this open-label trial of investigational DTX401 described positive experiences, including substantial reduction in burden and improved health-related quality of life following treatment throughout the trial. To optimize patient outcomes and experience with gene therapy, guidance on and close monitoring of dietary changes during implementation should be provided.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.155666","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:07:51Z","timestamp":1770912471000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":1,"title":["Trial Interviews to Explore Glycogen Storage Disease Type Ia Patient Experiences Following Gene Therapy"],"prefix":"10.36469","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-5704","authenticated-orcid":true,"given":"Diane M.","family":"Turner-Bowker","sequence":"first","affiliation":[{"name":"Ultragenyx Pharmaceutical, Inc., Novato, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Butler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00zbz2c25","id-type":"ROR","asserted-by":"publisher"}],"name":"Ultragenyx Pharmaceutical Inc., Novato, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Egan","sequence":"additional","affiliation":[{"name":"Lumanity, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Weinstein","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02der9h97","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Connecticut, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Rodriguez-Buritica","sequence":"additional","affiliation":[{"name":"University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Ahmad","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Luz","family":"Couce","sequence":"additional","affiliation":[{"name":"University Clinical Hospital of Santiago de Compostela, IDIS, CIBERER, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Riba-Wolman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02der9h97","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Connecticut, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Montr\u00e9al Children\u2019s Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Theodore-Oklota","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00zbz2c25","id-type":"ROR","asserted-by":"publisher"}],"name":"Ultragenyx Pharmaceutical Inc., Novato, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.36469\/001c.131811","article-title":"People and families affected by glycogen storage disease type Ia: an analysis of narrative accounts written by individuals living with GSDIa and their caregivers","volume":"12","author":"E. Kruger","year":"2025","journal-title":"J Health Econ Outcomes Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/8904_2013_283","article-title":"Quality of life in adult patients with glycogen storage disease type I: results of a multicenter Italian study","volume":"14","author":"A. Sechi","year":"2014","journal-title":"JIMD Rep"},{"issue":"7","key":"ref3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/jpepsy\/jsn017","article-title":"Psychosocial functioning in youth with glycogen storage disease type I","volume":"33","author":"E. Storch","year":"2008","journal-title":"J Pediatr Psychol"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70014","article-title":"Safety and efficacy of DTX401, an AAV8-mediated liver-directed gene therapy, in adults with glycogen storage disease type Ia (GSDIa)","volume":"48","author":"D. A. Weinstein","year":"2025","journal-title":"J Inherit Metab Dis"},{"key":"ref5","series-title":"The Discovery of Grounded Theory: Strategies for Qualitative Research","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-196807000-00014","article-title":"The discovery of grounded theory","author":"B. G. Glaser","year":"1967"},{"key":"ref6","series-title":"Rethinking Methods in Psychology","doi-asserted-by":"publisher","DOI":"10.4135\/9781446221792.n3","article-title":"Grounded theory","author":"K. Charmaz","year":"1995"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s41669-023-00397-z","article-title":"Estimation of health utility scores for glycogen storage disease type Ia","volume":"7","author":"E. Kruger","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"12","key":"ref8","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1016\/j.jval.2022.09.2009","article-title":"PCR74 Development of conceptual frameworks and patient-reported outcome measures in glycogen storage disease type Ia (GSDIa)","volume":"25","author":"J. Butler","year":"2022","journal-title":"Value Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.1484","article-title":"Qualitative interviews to characterize disease and treatment burden at baseline in adult and pediatric patients participating in a pivotal phase 3 trial of DTX401 for the treatment of glycogen storage disease type Ia","author":"D. M. Turner-Bowker","year":"2025"},{"key":"ref10","article-title":"OMIM","year":"2020","journal-title":"Johns Hopkins University"},{"issue":"3","key":"ref11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/s1043-2760(98)00123-4","article-title":"Molecular genetics of type 1 glycogen storage diseases","volume":"10","author":"J. Y. Chou","year":"1999","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1566524013364112","article-title":"The molecular basis of type 1 glycogen storage diseases","volume":"1","author":"J. Y. Chou","year":"2001","journal-title":"Curr Mol Med"},{"issue":"Pt 3","key":"ref13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/bj3620513","article-title":"The glucose-6-phosphatase system","volume":"362","author":"E. van Schaftingen","year":"2002","journal-title":"Biochem J"},{"issue":"10","key":"ref14","doi-asserted-by":"publisher","first-page":"e2221","DOI":"10.1002\/mgg3.2221","article-title":"Bedtime extended release cornstarch improves biochemical profile and sleep quality for patients with glycogen storage disease type Ia","volume":"11","author":"R. H. Hsu","year":"2023","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10545-014-9772-x","article-title":"Type I glycogen storage diseases: disorders of the glucose-6-phosphatase\/glucose-6-phosphate transporter complexes","volume":"38","author":"J. Y. Chou","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13023-015-0301-2","article-title":"Glycogen storage disease type Ia (GSDIa) but not glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation","volume":"10","author":"D. Melis","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/j.jval.2020.04.1292","article-title":"PRO71 The humanistic burden of glycogen storage disease type Ia: the impact on symptoms, diet, and health-related quality of life","volume":"23","author":"J. Butler","year":"2020","journal-title":"Value Health"},{"issue":"11","key":"ref18","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/nu13113828","article-title":"Glycogen storage disease type Ia: current management options, burden and unmet needs","volume":"13","author":"T. G. J. Derks","year":"2021","journal-title":"Nutrients"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/155666-trial-interviews-to-explore-glycogen-storage-disease-type-ia-patient-experiences-following-gene-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:35:44Z","timestamp":1779885344000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/155666-trial-interviews-to-explore-glycogen-storage-disease-type-ia-patient-experiences-following-gene-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.155666","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}